Biotech Values

[DewDiligence]

Thanks, aj. Getting back to the business model of KG/ALO… does this NYT article alter your opinion about whether some physicians will defensively gravitate to a pain med that contains a claim of abuse resistance in the FDA label?

If your answer to the above question is Yes, does your opinion change if the FDA label merely contains clinical data about abuse resistance rather than a full-fledged claim?

These two questions are germane to the economic value of a drug like Embeda. T.i.a.